Post Test Tatalaksana Retinopati Diabetik

Diagnostic modalities of diabetic retinopathy

• retinometer

• fundoscopy

• OCT

• FFA

The modality options for managing DME with good vision in protocol V are:

• focal lasers

• aflibercept

• observation

• not all three

indications of vitrectomy for diabetic retinopathy, except

• Nonclearing vitreous hemorrhage

• Tractional retinal detachment not threatening the macula

• Combined rhegmatogenous and tractional retinal detachment

• Dense pre-macular subhyaloid hemorrhage

which one is true about follow up severe NPDR with center-involved DME

• every month

• 2-4 months

• 3-4 months

• 6 months

characteristics of focal CSME, except :

• microaneurism

• FFA reveals focal leakage with adequate macular perfussion

• macular edema

• diffuse retinal edema and thickening throughout posterior pole

Below are the characteristic of severe DME

• retinal thickening

• hard exudate

• involving the centre of macula

• all true

when is the right time for early detection of diabetic retinopathy on type 2 DM?

• 2 years after diagnosed

• 3 months after diagnosed

• at time of diagnosis

• 5 years after diagnosed

Below is mechanism of Bevacizumab as Anti-VEGF agent

• competitively binds to the VEGF-A165 isoform at the heparin binding site

• binds to the receptor binding site for all isoforms of VEGF-A

• neutralizes all forms of VEGF-A

• soluble docoy receptor with high affinity for binding to VEGF molecules VEGF-A and PIGF

Indication of steroid use on DME

• phakic

• recurrent

• vitrectomized eye

• all true

antiVEGF that has been approved for use by the FDA for DME, except:

• ranibizumab

• aflibercept

• bevacizumab

• Elyea